Print this Page
About the Biosample Repository Core Facility
Risk Assessment at Fox Chase
Learning what you can do to lower your chances of getting cancer.
Read more »
Fox Chase has developed a facility dedicated to the collection and distribution of human subject biosamples (i.e., whole blood, plasma, DNA/RNA, and lymphocytes) and supporting personal and family cancer history data.
The Biosample Repository Core Facility (BRCF) is overseen by an interdivisional Advisory Committee (AC), with day-to-day staff supervision provided by Dr. Jeff Boyd.
Operations and protocols will be based on those originally implemented by Dr. Godwin, who is also the Director of the Clinical Molecular Genetic Laboratory, in support of the Risk Assessment Program.
How is this done?
Individuals attending a clinic at Fox Chase as well as relatives, employees and friends of FCCC are invited to sign an informed consent and contribute a blood sample, complete family history, risk factor and demographic questionnaires.
The White and Red cells are separated from the plasma.
Donated blood samples are separated into the following components: Lymphocytes are isolated from half of the blood, divided into multiple vials, and frozen in liquid nitrogen for future transformation or nucleic acid preparation. DNA is isolated from one quarter of donated blood and stored in dedicated mechanical freezers at -80 C. The remaining blood is used for the storage of plasma and blood spots.
Samples, as processed, are entered into a database. This database is used to track sample type, quantity, freezer location, and distribution. Available samples (whole blood, plasma, lymphocytes, and DNA/RNA) are distributed by the BRCF for use in interdivisional AC and IRB approved research projects at a minimal fee. The facility also supports special requests for the processing of human biosamples as part of grants awarded to FCCC investigators.
For more information about the Biosample Repository at Fox Chase Cancer Center, call (toll free) 1-888-831-6466 and ask for a recruitment coordinator.
Access to Biosamples by Researchers
In response to announcement (CA-00-025; P30 CA06927S2), the Fox Chase Cancer Center's Biosample Repository (BR) and Tumor Bank Facility (TBF) is making blood specimens (i.e., whole blood, plasma, platelet-rich plasma, platelet homogenates, red blood cells, leukocytes, lymphoblastoid cell lines, and DNA isolated from leukocytes) and tumor tissues (i.e., multi-tissue microarrays and tumor DNAs) collected by our facilities available for research. Request for blood and tissue will be reviewed by a panel of scientists and ranked. Priority will be given to those investigators with current NIGH/NCI funding, but will be made available as recommended by the internal and external advisor committees.
Access to Tissue and Blood Samples
